MBX Biosciences, Inc. Increase Decrease In Operating Lease Liability
MBX Biosciences, Inc. (MBX) reported Increase Decrease In Operating Lease Liability of $2.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- MBX Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was $2.79M, a 434.74% increase year-over-year.
- MBX Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$41.00K.
- MBX Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$27.00K.
- MBX Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$27.00K.
- MBX Biosciences, Inc. increase decrease in operating lease liability for fiscal 2025 was $425.00K.
- MBX Biosciences, Inc. increase decrease in operating lease liability for fiscal 2024 was -$153.00K.
- MBX Biosciences, Inc. increase decrease in operating lease liability for fiscal 2023 was -$137.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.75M 10-Q · filed 2026-08-06 | $2.72M derived: sum of 3 quarters · filed 2026-08-06 | $2.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$41.00K 10-Q · filed 2026-05-07 | -$68.00K derived: sum of 2 quarters · filed 2026-05-07 | -$95.00K derived: sum of 3 quarters · filed 2026-05-07 | $426.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$54.00K derived: sum of 2 quarters · filed 2026-03-12 | $467.00K derived: sum of 3 quarters · filed 2026-08-06 | $425.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $494.00K derived: sum of 2 quarters · filed 2026-08-06 | $452.00K 10-Q · filed 2025-11-06 | $412.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $521.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $479.00K 10-Q · filed 2026-08-06 | $439.00K derived: sum of 3 quarters · filed 2026-08-06 | $401.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$42.00K 10-Q · filed 2026-05-07 | -$82.00K derived: sum of 2 quarters · filed 2026-05-07 | -$120.00K derived: sum of 3 quarters · filed 2026-05-07 | -$158.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$78.00K derived: sum of 2 quarters · filed 2026-03-12 | -$116.00K derived: sum of 3 quarters · filed 2026-03-12 | -$153.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$76.00K derived: sum of 2 quarters · filed 2025-11-06 | -$113.00K 10-Q · filed 2025-11-06 | -$148.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$75.00K 10-Q · filed 2025-08-07 | -$110.00K derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$37.00K 10-Q · filed 2025-05-12 | -$72.00K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$137.00K 10-K · filed 2025-03-17 | ||
| 2023-09-30 | -$102.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |